Boston Scientific Valuation
| BSX Stock | USD 75.07 1.20 1.57% |
At this time, the firm appears to be undervalued. Boston Scientific Corp shows a prevailing Real Value of $88.0 per share. The current price of the firm is $75.07. Our model approximates the value of Boston Scientific Corp from analyzing the firm fundamentals such as Current Valuation of 123.88 B, profit margin of 0.14 %, and Return On Equity of 0.13 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Boston Scientific's valuation include:
Price Book 4.8348 | Enterprise Value | Enterprise Value Ebitda 26.7504 | Price Sales 5.6346 | Forward PE 22.0264 |
Undervalued
Today
Please note that Boston Scientific's price fluctuation is very steady at this time. Calculation of the real value of Boston Scientific Corp is based on 3 months time horizon. Increasing Boston Scientific's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Boston Scientific is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Boston Stock. However, Boston Scientific's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.07 | Real 88.0 | Target 106.78 | Hype 74.48 |
The intrinsic value of Boston Scientific's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Boston Scientific's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Boston Scientific Corp helps investors to forecast how Boston stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Boston Scientific more accurately as focusing exclusively on Boston Scientific's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Boston Scientific's intrinsic value based on its ongoing forecasts of Boston Scientific's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Boston Scientific's closest peers.
Boston Scientific Cash |
|
Boston Revenue by Product
Boston Scientific Total Value Analysis
Boston Scientific Corp is currently projected to have company total value of 123.88 B with market capitalization of 113.11 B, debt of 11.15 B, and cash on hands of 414 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Boston Scientific fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
123.88 B | 113.11 B | 11.15 B | 414 M |
Boston Scientific Investor Information
About 95.0% of the company shares are held by institutions such as insurance companies. The book value of Boston Scientific was currently reported as 15.78. The company has Price/Earnings To Growth (PEG) ratio of 0.85. Boston Scientific Corp had not issued any dividends in recent years. The entity had 2:1 split on the 6th of November 2003. Based on the measurements of operating efficiency obtained from Boston Scientific's historical financial statements, Boston Scientific Corp may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.2 | 0.1978 |
|
| |||||
| Total Cash From Operating Activities | 4.1 B | 4 B |
|
| |||||
| Operating Income | 4.2 B | 4 B |
|
|
Boston Scientific Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Boston Scientific has an asset utilization ratio of 50.96 percent. This suggests that the Company is making $0.51 for each dollar of assets. An increasing asset utilization means that Boston Scientific Corp is more efficient with each dollar of assets it utilizes for everyday operations.Boston Scientific Profitability Analysis
Based on the measurements of profitability obtained from Boston Scientific's financial statements, Boston Scientific Corp is yielding more profit at this time then in previous quarter. It has a moderate probability of reporting better profitability numbers in March. Profitability indicators assess Boston Scientific's ability to earn profits and add value for shareholders.Net Income | First Reported 1991-03-31 | Previous Quarter 755 M | Current Value 668 M | Quarterly Volatility 675.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.73 | 0.6901 |
|
| |||||
| Operating Profit Margin | 0.2 | 0.1978 |
|
|
For Boston Scientific profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Boston Scientific Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Boston Scientific utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Boston Scientific's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Boston Scientific over time as well as its relative position and ranking within its peers.
Boston Scientific Earnings per Share Projection vs Actual
The next projected EPS of Boston Scientific is estimated to be 0.8705 with future projections ranging from a low of 0.85 to a high of 0.9. Boston Scientific's most recent 12-month trailing earnings per share (EPS TTM) is at 1.94. Please be aware that the consensus of earnings estimates for Boston Scientific Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Boston Scientific Earnings Estimation Breakdown
The calculation of Boston Scientific's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Boston Scientific is estimated to be 0.8705 with the future projection ranging from a low of 0.85 to a high of 0.9. Please be aware that this consensus of annual earnings estimates for Boston Scientific Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.85 Lowest | Expected EPS | 0.90 Highest |
Boston Scientific Earnings Projection Consensus
Suppose the current estimates of Boston Scientific's value are higher than the current market price of the Boston Scientific stock. In this case, investors may conclude that Boston Scientific is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Boston Scientific's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 34 | 91.58% | 0.0 | 0.8705 | 1.94 |
Boston Scientific Ownership Allocation
Boston Scientific holds a total of 1.48 Billion outstanding shares. The majority of Boston Scientific Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Boston Scientific Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Boston Scientific. Please pay attention to any change in the institutional holdings of Boston Scientific Corp as this could imply that something significant has changed or is about to change at the company. Please note that on January 16, 2026, Senator Markwayne Mullin of US Senate acquired $15k to $50k worth of Boston Scientific Corp's common stock.Boston Scientific Profitability Analysis
The company reported the last year's revenue of 20.07 B. Total Income to common stockholders was 1.85 B with profit before taxes, overhead, and interest of 14.1 B.About Boston Scientific Valuation
Our relative valuation model uses a comparative analysis of Boston Scientific. We calculate exposure to Boston Scientific's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Boston Scientific's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 13.9 B | 14.5 B | |
| Pretax Profit Margin | 0.17 | 0.18 | |
| Operating Profit Margin | 0.20 | 0.20 | |
| Net Profit Margin | 0.14 | 0.15 | |
| Gross Profit Margin | 0.69 | 0.73 |
Boston Scientific Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.5 B | |
| Quarterly Earnings Growth Y O Y | 0.185 | |
| Forward Price Earnings | 22.0264 |
Boston Scientific Current Valuation Indicators
Valuation refers to the process of determining the present value of Boston Scientific Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Boston we look at many different elements of the entity such as Boston's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Boston Scientific, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Boston Scientific's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Boston Scientific's worth.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.